GI-10001

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameGI-10001

Drug Alias Namechronic myelogenous leukemia therapy (GlobeImmune)GI-10000GI-10001

ClassificationVaccines > Development/production technology > Recombinant vector vaccineVaccines > Application > Therapeutic vaccineBiologics > Antigen > Tumor antigen

Mechanisms of ActionBcr-Abl tyrosine kinase modulators

TargetsBcr-Abl tyrosine kinase

Therapy Area/IndicationsLeukemia, Myelogenous, Chronic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesGlobeimmune Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGlobeimmune Inc

Active IndicationsN/A

Inactive IndicationsLeukemia, Myelogenous, Chronic

Other Information

ATC CodeN/A